Polycythemia Vera Epidemiology Forecast

DelveInsight's 'Polycythemia Vera - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Polycythemia Vera epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Polycythemia Vera Understanding

Polycythemia Vera (PV) is a condition characterized by an increased number of red blood cells in the bloodstream (erythrocytosis) and affected people may also have excess white blood cells and platelets. Most cases of PV are not inherited and are acquired during a person’s lifetime.


PV is diagnosed by testing the blood for levels of a hormone called erythropoietin as well as testing the blood for mutations in JAK2 or TET2. If mutations are not found in the red blood cells but the doctors still suspect a diagnosis of polycythemia vera, a bone marrow biopsy may be done to look for mutations in the hematopoietic blood cells which are located in the bone marrow.


The most precarious symptom of polycythemia vera is the chance for a thrombotic event that can cause a heart attack or stroke. There is also a small chance that polycythemia vera could cause an individual to develop leukemia. With proper treatment, however, these symptoms have not been shown to greatly affect the expected lifespan of a person with polycythemia vera. Another complication i.e. itching (pruritus) patients can manage with the help of various medicines.

Polycythemia Vera Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of PV, Prevalence Population of PV Based on Symptoms, Gender-specific Symptomatic Prevalence of PV, Age-specific Symptomatic Prevalence of PV, Prevalence of PV Based on Risk, and Prevalence of PV by Gene Mutation scenario of PV in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

Polycythemia Vera Detailed Epidemiology Segmentation

The Polycythemia Vera epidemiology covered in the report provides historical as well as forecasted Polycythemia Vera epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.


The DelveInsight Polycythemia Vera report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


  • The total prevalent population of PV in the 7MM was 283,442 in 2017.
  • The estimates show the highest prevalence of PV in the United States with 157,290 cases in 2017.
  • DelveInsight’s epidemiology model for PV estimates that out of the total population of 157,290 cases in the US for PV, 62,916 cases and 94,374 cases were contributed by asymptomatic and symptomatic, respectively.
  • Among the European five countries, Germany had the highest symptomatic prevalent population of PV with 14,502 cases, followed by France and the United Kingdom. Japan had 18,954 symptomatic prevalent cases for PV in 2017.
  • As per the analysis, a higher percentage of prevalence was observed for males, in comparison to females, in all the 7MM countries. Out of the total symptomatic population in the US for PV, 61,060 cases and 33,314 cases were contributed by males and females in 2017.
  • It has been also observed that PV in the US is mostly prevalent in the age group of >75 years.
  • A total of 94,374 diagnosed (symptomatic) prevalent population of PV was assessed in 2017. Out of these cases, ~87,881 cases of PV were calculated for patients with JAK2 V617F, thereby accounting for the highest number of cases with gene mutation with ~97% of total PV cases with JAK2 mutation.
  • Around 23% of patients accounted for low-risk categories, and 77% accounted for high-risk cases in 2017 in the United States.


Scope of the Report

  • The Polycythemia Vera report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Polycythemia Vera Epidemiology Report and Model provide an overview of the risk factors and global trends of Polycythemia Vera in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Polycythemia Vera in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Polycythemia Vera
  • The report provides the segmentation of the Polycythemia Vera epidemiology


Report Highlights

  • 11-Year Forecast of Polycythemia Vera epidemiology
  • 7MM Coverage
  • Total Cases of Polycythemia Vera
  • Total Cases of Polycythemia Vera according to segmentation
  • Diagnosed cases of Polycythemia Vera


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Polycythemia Vera?
  • What are the key findings pertaining to the Polycythemia Vera epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Polycythemia Vera across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Polycythemia Vera?
  • What are the currently available treatments of Polycythemia Vera?


Reasons to buy

  • The Polycythemia Vera Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Polycythemia Vera market
  • Quantify patient populations in the global Polycythemia Vera market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Polycythemia Vera therapeutics in each of the markets covered
  • Understand the magnitude of Polycythemia Vera population by its epidemiology
  • The Polycythemia Vera Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Polycythemia Vera

3. Polycythemia Vera: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Polycythemia Vera Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Polycythemia Vera Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Polycythemia Vera Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Polycythemia Vera Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Polycythemia Vera Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Polycythemia Vera Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Polycythemia Vera Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Polycythemia Vera Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Polycythemia Vera Treatment and Management

6.2. Polycythemia Vera Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1  Polycythemia Vera Epidemiology in 7MM (2017-2030)

Table 2 Polycythemia Vera Diagnosed and Treatable Cases in 7MM (2017-2030)

Table 3 Polycythemia Vera Epidemiology in the United States (2017-2030)

Table 4 Polycythemia Vera Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 Polycythemia Vera Epidemiology in Germany (2017-2030)

Table 6 Polycythemia Vera Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 Polycythemia Vera Epidemiology in France (2017-2030)

Table 8 Polycythemia Vera Diagnosed and Treatable Cases in France (2017-2030)

Table 9 Polycythemia Vera Epidemiology in Italy (2017-2030)

Table 10 Polycythemia Vera Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 Polycythemia Vera Epidemiology in Spain (2017-2030)

Table 12 Polycythemia Vera Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 Polycythemia Vera Epidemiology in the United Kingdom (2017-2030)

Table 14 Polycythemia Vera Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Table 15 Polycythemia Vera Epidemiology in Japan (2017-2030)

Table 16 Polycythemia Vera Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 1 Polycythemia Vera Epidemiology in 7MM (2017-2030)

Figure 2 Polycythemia Vera Diagnosed and Treatable Cases in 7MM (2017-2030)

Figure 3 Polycythemia Vera Epidemiology in the United States (2017-2030)

Figure 4 Polycythemia Vera Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 Polycythemia Vera Epidemiology in Germany (2017-2030)

Figure 6 Polycythemia Vera Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 Polycythemia Vera Epidemiology in France (2017-2030)

Figure 8 Polycythemia Vera Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 Polycythemia Vera Epidemiology in Italy (2017-2030)

Figure 10 Polycythemia Vera Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 Polycythemia Vera Epidemiology in Spain (2017-2030)

Figure 12 Polycythemia Vera Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 Polycythemia Vera Epidemiology in the United Kingdom (2017-2030)

Figure 14 Polycythemia Vera Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Figure 15 Polycythemia Vera Epidemiology in Japan (2017-2030)

Figure 16 Polycythemia Vera Diagnosed and Treatable Cases in Japan (2017-2030)

*The table of contents is not exhaustive; will be provided in the final report


  • Tags:
  • Polycythemia Vera Epidemiology
  • Polycythemia Vera
  • Polycythemia Vera Pipeline
  • Polycythemia Vera Companies
  • Polycythemia Vera prevalent popula...
  • Polycythemia Vera incident populat...
  • Polycythemia Vera patients diagnos...
  • Polycythemia Vera treatment algori...

Forward to Friend

Need A Quote